Vaccination against porcine reproductive and respiratory syndrome virus (PRRSV) reduces the magnitude and duration of viremia following challenge with a virulent heterologous field strain.

[1]  R. Thanawongnuwech,et al.  Efficacy of Fostera® PRRS modified live virus (MLV) vaccination strategy against a Thai highly pathogenic porcine reproductive and respiratory syndrome virus (HP-PRRSV) infection , 2016, Tropical Animal Health and Production.

[2]  C. Chae,et al.  Comparison of commercial type 1 and type 2 PRRSV vaccines against heterologous dual challenge , 2016, Veterinary Record.

[3]  C. Gagnon,et al.  Efficacy of Fostera PRRS modified live virus vaccine against a Canadian heterologous virulent field strain of porcine reproductive and respiratory syndrome virus. , 2016, Canadian journal of veterinary research = Revue canadienne de recherche veterinaire.

[4]  T. Opriessnig,et al.  Chimeric porcine reproductive and respiratory syndrome virus containing shuffled multiple envelope genes confers cross-protection in pigs. , 2015, Virology.

[5]  C. Chae,et al.  Comparison of two genetically distant type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against Vietnamese highly pathogenic PRRSV. , 2015, Veterinary microbiology.

[6]  Xiang‐Jin Meng,et al.  Live porcine reproductive and respiratory syndrome virus vaccines: Current status and future direction. , 2015, Vaccine.

[7]  J. Bates,et al.  Pigs immunized with Chinese highly pathogenic PRRS virus modified live vaccine are protected from challenge with North American PRRSV strain NADC-20. , 2015, Vaccine.

[8]  C. Chae,et al.  Cross-protection of a new type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccine (Fostera PRRS) against heterologous type 1 PRRSV challenge in growing pigs. , 2015, Veterinary microbiology.

[9]  I. Díaz,et al.  Vaccination with a genotype 1 modified live vaccine against porcine reproductive and respiratory syndrome virus significantly reduces viremia, viral shedding and transmission of the virus in a quasi-natural experimental model. , 2015, Veterinary microbiology.

[10]  C. Chae,et al.  Evaluation of the efficacy of a new modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Fostera PRRS) against heterologous PRRSV challenge. , 2014, Veterinary microbiology.

[11]  J. Lunney,et al.  Quantitative Analysis of Porcine Reproductive and Respiratory Syndrome (PRRS) Viremia Profiles from Experimental Infection: A Statistical Modelling Approach , 2013, PloS one.

[12]  S. Dee,et al.  Effect of modified-live porcine reproductive and respiratory syndrome virus (PRRSv) vaccine on the shedding of wild-type virus from an infected population of growing pigs. , 2012, Vaccine.

[13]  C. Corzo,et al.  Long-distance airborne transport of infectious PRRSV and Mycoplasma hyopneumoniae from a swine population infected with multiple viral variants. , 2010, Veterinary microbiology.

[14]  James Kliebenstein,et al.  Assessment of the economic impact of porcine reproductive and respiratory syndrome virus on United States pork producers , 2013, Journal of Swine Health and Production.

[15]  J. Calvert,et al.  CD163 Expression Confers Susceptibility to Porcine Reproductive and Respiratory Syndrome Viruses , 2007, Journal of Virology.

[16]  G. Kärber,et al.  Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche , 1931, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.

[17]  J. Sur,et al.  Duration of Infection and Proportion of Pigs Persistently Infected with Porcine Reproductive and Respiratory Syndrome Virus , 2003, Journal of Clinical Microbiology.

[18]  J. Zimmerman,et al.  Characterization of the carrier state in porcine reproductive and respiratory syndrome virus infection. , 2002, Veterinary microbiology.